Table 1. List of published TCR-T cell clinical trials.

Symbols: (), response duration in months after treatment; +, ongoing. Abbreviations: TDAs, tissue differentiation antigens; CGAs, cancer germline antigens; CR, complete response; PR, partial response by RECIST criteria; CEA, carcinoembryonic antigen; gp100, glycoprotein 100; HPV, human papillomavirus; MAGE-A, melanoma-associated antigen; MART-1, melanoma antigen recognized by T cells 1; NY-ESO-1, New York esophageal squamous cell carcinoma-1; MPNST, malign peripheral nerve sheath tumors; NSCLC, non–small cell lung cancer; CRS, cytokine release syndrome; n.s., not specified; KO-KI, knockout–knock-in; N.A., not available.

Antigen type	Target antigen	Epitope	HLA	Cancer type	Vector	Number of cells	Number of patients	Clinical trial	Phase	Objective response rate (ORR) (%)	Clinical response (months)	Toxicities related to TCR-T cells (%)	Reference
TDAs	MART-1	AAGIGILTV	HLA-A*02:01	Melanoma	Retrovirus	0.5 to 34 × 109	17	n.s.	n.s.	2 (12%)	2 PR (20, 21)	None	Morgan et al. (10)
	MART-1	AAGIGILTV	HLA-A*02:01	Melanoma	Retrovirus	0.15 to 10 × 1010	20	NCT00509288	II	6 (30%)	6 PR (3, 4, 9, 17+, 17+)	Skin rash: 14 (70%)	Johnson et al. (11)
												Uveitis: 11 (55%)
												Hearing loss: 10 (50%)
	MART-1	EAAGIGILTV	HLA-A*02:01	Melanoma	Retrovirus	0.6 to 4.8 × 109	13	NCT00910650	II	0		Skin rash: 3 (23%)	Chodon et al. (12)
												CRS: 2 (15%)
	MART-1	EAAGIGILTV	HLA-A*02:01	Melanoma	Retrovirus	0.05 to 4.56 × 109	12	NCT02654821	I/IIa	2 (16.7%)	2 PR (4.1, 7.1)	CRS/sepsis: 1 (8%)	Rohaan et al. (13)
												Dermatitis: 10 (83%)
												Uveitis: 2 (17%)
												Hearing loss: 4 (33%)
	gp100	KTWGQYWQV	HLA-A*02:01	Melanoma	Retrovirus	0.18 to 11 × 1010	16	NCT00509496	II	3 (16%)	1 CR (14+)	Skin rash: 15 (94%)	Johnson et al. (11)
												Uveitis: 4 (25%)
											2 PR (4, 3)	Hearing loss: 5 (31%)
	CEA	IMIGVLVGV	HLA-A*02:01	Colorectal cancer	Retrovirus	2 to 4 × 108	3	NCT00923806	I	1 (33%)	1 PR (6)	Severe transient colitis: 3 (100%)	Parkhurst et al. (14)
CGAs	MAGE-A3	KVAELVHFL	HLA-A*02:01	Melanoma	Retrovirus	2.8 to 7.9 × 1010	9 (7 + 1 + 1)	NCT01273181	I/II	5 (56%)	1 CR (15+)	Severe neurologic toxicity: 3 (33%) including 2 deaths	Morgan et al. (16)
				Synovial sarcoma							4 PR (4, 4, 5, 12+)
				Esophageal cancer
	MAGE-A3	EVDPIGHLY	HLA-A*01	Melanoma	Lentivirus	2.4 to 5.3 × 109	2 (1 + 1)	NCT01350401	I	0		Severe cardiac toxicity and death: 2 (100%)	Linette et al. (17)
				Myeloma				NCT01352286
	MAGE-A3		HLA-DPB1*0401	Metastatic solid tumors	Retrovirus	0.01 to 123 × 109	17	NCT02111850	I	4 (23.5%)	1 CR (29+) 3 PR (4, 4, 18+)	Liver toxicity: 2 (12%)	Lu et al. (18)
	MAGE-A4	NYKRCFPVI	HLA-A*24:02	Esophageal cancer	Retrovirus	0.2 to 5 × 109	10	UMIN000002395	I	0	none	Kageyama et al. (19)
	MAGE-A4	GVYDGREHTV	HLA-A*02	Advanced solid tumors	Lentivirus	0.12 to 10 × 109	38	NCT03132922	I	9 (23.7%)	9 PR	CRS: 9 (50%)	Hong et al. (20)
	MAGE-A10	GLYDGMEHL	HLA-A*02:01 or HLA-A*02:06	NSCLC	Lentivirus	0.1 to 6.77.109	11	NCT02592577	I	1 (9%)	1 PR (1)	CRS: 3 (27%)	Blumenschein et al. (21)
												Neurotoxicity: 1 (9%)
	NY-ESO-1	SLLMWITQC	HLA-A*02:01	Melanoma	Retrovirus	0.16 to 13 × 1010	17 (11 + 6)	NCT00670748	I	5 (45%) 4 (67%)	2 CR (20+, 22+)	None	Robbins et al. (22)
				Synovial sarcoma							3 PR (3, 8, 9+)
											4 PR (5, 8, 10, 18)
	NY-ESO-1	SLLMWITQC	HLA-A*02:01	Melanoma	Retrovirus	0.9 to 13 × 1010	38 (20 + 16)	NCT00670748	II	11 (55%) 11 (61%)	4 CR (24, 40+, 54+, 58+)	None	Robbins et al. (23)
											7 PR (3, 3, 5, 6+, 8, 10, 28)
				Synovial sarcoma							1 CR (6)
											10 PR (3, 3, 4, 5, 7, 8, 10, 11, 18, 47+)
	NY-ESO-1	SLLMWITQC	HLA-A*02:01	Melanoma	Retrovirus	1 × 109	10	NCT02070406	I	2 (20%)	2 PR	CRS: 1 (10%)	Nowicki et al. (24)
				Synovial sarcoma
				Liposarcoma				NCT01697527
				Osteosarcoma
				MPNST
	NY-ESO-1	SLLMWITQC	HLA-A*02:01 HLA-A*02:06	Synovial sarcoma	Lentivirus	0.4 to 14.4 × 109	12	NCT01343043	I/II	6 (50%)	1 CR (8)	CRS: 5 (42%)	D’Angelo et al. (25)
											5 PR (4, 7, 8, 18)
		NY-ESO-1SLLMWITQC	HLA-A*02:01 HLA-A*02:06	Synovial sarcoma	Lentivirus	2.67 × 109	30	NCT01343043	I/II	9 (30%)	9 PR (2-13)	n.s.	Ramachandran et al. (26)
		NY-ESO-1(CRISPR -Cas9)SLLMWITQC	HLA-A*02:01	Liposarcoma Myeloma	Lentivirus	0.6 to 7.1 × 108	3	NCT03399448	I	0		None	Stadtmauer et al. (27)
Viral antigens	HPV16-E6	TIHDIILECV	HLA-A*02:01	HPV16-positive epithelial cancer	Retrovirus	0.1 to 13.4 × 1010	12	NCT02280811	I/II	2 (17%)	2 PR (3, 6)	None	Doran et al. (38)
	HPV16-E7	YMLDLQPET	HLA-A*02:01	HPV16-positive epithelial cancer	Retrovirus	0.1 to 12.1010	12	NCT02858310	I	6 (50%)	6 PR (3, 4, 4, 8, 8, 9)	None	Nagarsheth et al. (39)
	HBV	N.A.	HLA-A*02 or HLA-Cw0801	HBV-HCC	Electroporation	1 × 104/kg to 5 × 106/kg	8	NCT03899415	I	1	1 PR (27.7)	Liver toxicity: 1 (12%)	Meng et al. (40)
	MCPyV	KLLEIAPNC	HLA-A*02:01	Merkel cell carcinoma	Lentivirus	1 to 9 × 108	5	NCT03747484	I	1 (25%)	n.s.	None	Veatch et al. (41)
Neo-antigens	TP53	HMTEVVRHC	HLA-A*02:01	Metastatic breast cancer	Retrovirus	5.3 × 1010	1	NCT03412877	I	1 (100%)	1 PR (6)	CRS	Kim et al. (34)
	KRAS G12D	GADGVGKSA	HLA-C*08:02	Metastatic pancreatic cancer	Retrovirus	1.6.1010	1	IND 27501	I	1 (100%)	1 PR (6+)	None	Leidner et al. (35)
		GADGVGKSAL
	Mutation-associated neoantigens (CRISPR-Cas9 KO-KI)		Multiple HLA class I	Metastatic solid tumors	Electroporation	0.13 to 4.109	16	NCT03970382	I	0		CRS: 1 (6%)	Foy et al. (37)
												Neurotoxicity: 1 (6%)